These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 23997919)

  • 1. The effect of solvent treatment on the performance of various carriers in dry powder inhalations containing salbutamol sulphate.
    Siahai Shadbad MR; Millen L; Momin M; Nokhodchi A
    Iran J Basic Med Sci; 2013 Jul; 16(7):873-81. PubMed ID: 23997919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineered mannitol ternary additives improve dispersion of lactose-salbutamol sulphate dry powder inhalations.
    Kaialy W; Nokhodchi A
    AAPS J; 2013 Jul; 15(3):728-43. PubMed ID: 23591748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-spraying of carriers (mannitol-lactose) as a method to improve aerosolization performance of salbutamol sulfate dry powder inhaler.
    Ferdynand MS; Nokhodchi A
    Drug Deliv Transl Res; 2020 Oct; 10(5):1418-1427. PubMed ID: 31933129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engineered mannitol as an alternative carrier to enhance deep lung penetration of salbutamol sulphate from dry powder inhaler.
    Kaialy W; Momin MN; Ticehurst MD; Murphy J; Nokhodchi A
    Colloids Surf B Biointerfaces; 2010 Sep; 79(2):345-56. PubMed ID: 20537870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dry powder inhaler performance of spray dried mannitol with tailored surface morphologies as carrier and salbutamol sulphate.
    Mönckedieck M; Kamplade J; Fakner P; Urbanetz NA; Walzel P; Steckel H; Scherließ R
    Int J Pharm; 2017 May; 524(1-2):351-363. PubMed ID: 28347847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of carrier particle shape on dry powder inhaler performance.
    Kaialy W; Alhalaweh A; Velaga SP; Nokhodchi A
    Int J Pharm; 2011 Dec; 421(1):12-23. PubMed ID: 21945739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of engineered mannitol-lactose mixture on dry powder inhaler performance.
    Kaialy W; Larhrib H; Martin GP; Nokhodchi A
    Pharm Res; 2012 Aug; 29(8):2139-56. PubMed ID: 22477070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of different grades of lactose as a carrier for aerosolised salbutamol sulphate.
    Larhrib H; Zeng XM; Martin GP; Marriott C; Pritchard J
    Int J Pharm; 1999 Nov; 191(1):1-14. PubMed ID: 10556735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The enhanced aerosol performance of salbutamol from dry powders containing engineered mannitol as excipient.
    Kaialy W; Martin GP; Ticehurst MD; Momin MN; Nokhodchi A
    Int J Pharm; 2010 Jun; 392(1-2):178-88. PubMed ID: 20363301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterisation and deposition studies of recrystallised lactose from binary mixtures of ethanol/butanol for improved drug delivery from dry powder inhalers.
    Kaialy W; Martin GP; Ticehurst MD; Royall P; Mohammad MA; Murphy J; Nokhodchi A
    AAPS J; 2011 Mar; 13(1):30-43. PubMed ID: 21057906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lactose as a carrier in dry powder formulations: the influence of surface characteristics on drug delivery.
    Zeng XM; Martin GP; Marriott C; Pritchard J
    J Pharm Sci; 2001 Sep; 90(9):1424-34. PubMed ID: 11745794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of carrier and drug morphology on drug delivery from dry powder formulations.
    Larhrib H; Martin GP; Marriott C; Prime D
    Int J Pharm; 2003 May; 257(1-2):283-96. PubMed ID: 12711183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carrier-based dry powder inhalation: Impact of carrier modification on capsule filling processability and in vitro aerodynamic performance.
    Faulhammer E; Wahl V; Zellnitz S; Khinast JG; Paudel A
    Int J Pharm; 2015 Aug; 491(1-2):231-42. PubMed ID: 26136200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Humidity-induced changes of the aerodynamic properties of dry powder aerosol formulations containing different carriers.
    Zeng XM; MacRitchie HB; Marriott C; Martin GP
    Int J Pharm; 2007 Mar; 333(1-2):45-55. PubMed ID: 17064863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of physical properties and morphology of crystallised lactose on delivery of salbutamol sulphate from dry powder inhalers.
    Kaialy W; Martin GP; Larhrib H; Ticehurst MD; Kolosionek E; Nokhodchi A
    Colloids Surf B Biointerfaces; 2012 Jan; 89():29-39. PubMed ID: 21962946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Particle engineered mannitol for carrier-based inhalation - A serious alternative?
    Hertel N; Birk G; Scherließ R
    Int J Pharm; 2020 Mar; 577():118901. PubMed ID: 31846726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of carrier size and morphology on the dispersion of salbutamol sulphate after aerosolization at different flow rates.
    Zeng XM; Martin GP; Marriott C; Pritchard J
    J Pharm Pharmacol; 2000 Oct; 52(10):1211-21. PubMed ID: 11092565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Performance tuning of particle engineered mannitol in dry powder inhalation formulations.
    Hertel N; Birk G; Scherließ R
    Int J Pharm; 2020 Aug; 586():119592. PubMed ID: 32622814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dry powder inhalers: physicochemical and aerosolization properties of several size-fractions of a promising alterative carrier, freeze-dried mannitol.
    Kaialy W; Nokhodchi A
    Eur J Pharm Sci; 2015 Feb; 68():56-67. PubMed ID: 25497318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of different sugars as fine and coarse carriers for aerosolised salbutamol sulphate.
    Tee SK; Marriott C; Zeng XM; Martin GP
    Int J Pharm; 2000 Nov; 208(1-2):111-23. PubMed ID: 11064216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.